Monika Kakol, MD
Pulmonary Disease · Los Angeles, CANPI 1861807794
Payments from drug & device makers
Across 70 payments — averaging $125.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pulmonx Corporation$2K
- Steris Corporation$2K
- Intuitive Surgical$1K
- Pinnacle Biologics, Inc$1K
- Johnson & Johnson$1K
- Medtronic$1K
- plus $993 from 6 others
What the payments were for
- Travel & lodging$5,68164%
- Food & beverage$2,63030%
- Education$5006%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pulmonx Corporation | 9 | $1,605 |
| Steris Corporation | 7 | $1,573 |
| Intuitive Surgical | 7 | $1,352 |
| Pinnacle Biologics, Inc | 5 | $1,198 |
| Johnson & Johnson | 10 | $1,078 |
| Medtronic | 15 | $1,014 |
| Olympus America Inc. | 10 | $588 |
| Bayer | 3 | $175 |
| United Therapeutics Corporation | 1 | $125 |
| Noah Medical Corporation | 1 | $56 |
| ZOLL Respicardia, Inc. | 1 | $25 |
| GSK | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRUFREEZE$1,428
- ZEPHYR ENDOBRONCHIAL VALVE$1,311
- Da Vinci Surgical System$1,210
- Photofrin$1,099
- Monarch Platform$973
- ILLUMISITE$740
- REMODULIN$125
- TYVASO$125
- NONE$125
- Single-Use flexible Video Bronchoscope$114
- Always-On Tip Tracked Forceps, 1.8mm OD, Serrated Cup$109
How this compares
$8,812 in reported general payments places this provider in the 75th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Los Angeles
- Toby MaherLos Angeles$27.6M
- Andrew WachtelLos Angeles$5.9M
- Michael RothLos Angeles$4.5M
- Rajan SaggarLos Angeles$3.3M
- Stephen Samuel WeigtLos Angeles$2.1M
- Robert WolfeLos Angeles$1.9M
- Igor BarjaktarevicLos Angeles$1.9M
- Shelley ShapiroLos Angeles$1M
- Victor TapsonLos Angeles$931K
- John BelperioLos Angeles$905K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.